MedTrace Logo

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

NCT03486457 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2024-02-08

Study results available
· View outcomes & findings →

Summary

This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.

Conditions

Interventions

DRUG

Tofacitinib

tablets, 5 mg BID x 6 months

OTHER

Placebo

tablets, to match tofacitinib 5 mg BID x 3 months

DRUG

Tofacitinib

tablets, 5 mg BID x 3 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2021-04-28
Completion
2021-04-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03486457 on ClinicalTrials.gov